24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma: comparison with placebo and formoterol

ABSTRACT

Objective: To assess the 24-h bronchodilator efficacy and safety of single-dose indacaterol in asthma.

Methods: This was a five-period, double-blind, double-dummy, crossover study in patients with persistent asthma. On separate study days, patients inhaled a single dose of indacaterol (150, 300 or 600?µg) in the morning via a single-dose dry powder inhaler (SDDPI), formoterol 12?µg twice daily via its proprietary SDDPI, or placebo. Study days were separated by a washout period of at least 6 days.

Results: Of the 45 patients randomized to treatment, 42 completed the study. The 24-h trough FEV₁ (primary endpoint) was significantly higher than placebo following all doses of indacaterol (mean [95% CI] differences of 0.11 [0.06, 0.16], 0.21 [0.17, 0.26] and 0.22 [0.18, 0.27] L for 150, 300, and 600?µg, respectively) and formoterol (by 0.13 [0.08, 0.18] L). The 24-h trough FEV₁ was significantly higher following indacaterol 300 and 600?µg than indacaterol 150?µg (by 0.11 [0.06, 0.15] and 0.12 [0.07, 0.17] L, respectively) or formoterol (by 0.08 [0.03, 0.13] L vs. 300?µg; by 0.09 [0.04, 0.14] L vs. 600?µg). Most adverse events were mild-to-moderate and transient. Examination of serum potassium, blood glucose, QTc interval, pulse rate, and blood pressure raised no concern over the safety of indacaterol.

Conclusions: Single doses of indacaterol provided effective 24-h bronchodilation and were well tolerated in patients with persistent asthma. Safety findings were limited by non-standardized diet conditions in this study but suggest a minimal systemic treatment effect.     

布地奈德／福莫特罗吸入剂治疗妊娠期哮喘疗效观察

目的探讨布地奈德／福莫特罗干粉吸入剂治疗妊娠期哮喘的临床效果和不良反应。方法64例妊娠期哮喘患者按疾病严重程度使用不同剂量的布地奈德／福莫特罗吸入剂,连续应用6个月以上,期间予以随访及哮喘管理,根据哮喘控制程度评分（ACT）比较应用前后疾病控制情况,观察肺功能变化及不良反应。结果根据患者ACT问卷,治疗前达到哮喘控制的患者为4．7％（3／64）、部分控制为62．5％（40／64）、未控制为32．8％（21／64）。治疗后6个月,控制、部分控制及未控制分别为48．4％（31／64）、部分控制为42．2％（27／64）、未控制为9．4％（6／64）,治疗前后哮喘控制情况差异有统计学意义（Z：5．73,P〈0．05）。治疗后6个月,第一秒钟用力呼气容积占预计值百分比及最大呼气流速占预计值百分比均明显提高（均P〈0．05）。无严重并发症发生。结论布地奈德／福莫特罗干粉吸入剂对妊娠期哮喘患者具有良好的治疗效果和安全性。     

Superiority of fluticasone propionate/formoterol fumarate versus fluticasone propionate alone in patients with moderate-to-severe asthma: a randomised controlled trial

Abstract

Objective:

To demonstrate the efficacy and safety of fluticasone propionate/formoterol fumarate (flutiform) in a pressurised metered-dose inhaler (pMDI) compared to two formulations of the fluticasone propionate component (Skyepharma fluticasone [SKP FP] or Flovent, GlaxoSmithKline [GSK FP]) in adults and adolescents with moderate-to-severe asthma.     

The effect of adjustable dosing with budesonide/formoterol on health-related quality of life and asthma control compared with fixed dosing

SUMMARY

Background: Budesonide/formoterol in a single inhaler is an effective therapy for asthma. We investigated whether adjustable maintenance dosing with budesonide/formoterol could maintain health-related quality of life (HRQL) and asthma control.

Patients/methods: Asthma patients (n = 4025) received budesonide/formoterol (Symbicort* 160/4.5?µg) 2 inhalations twice daily (bid) for 4?weeks during run-in of this open, multicentre study. Patients were randomised to adjustable dosing (budesonide/formoterol 1 inhalation bid; stepping up to 2 or 4 inhalations bid for 1?week if asthma worsened) or fixed dosing (budesonide/formoterol 2 inhalations bid), for 12?weeks. Change in HRQL (standardised Asthma Quality of Life Questionnaire, AQLQ[S], score) during randomised treatment was the primary efficacy variable. Secondary variables included asthma control (peak expiratory flow [PEF], symptom-severity score, nocturnal awakenings, reliever-medication use) and study-medication intake.

Results: Clinically significant (≥ 0.5) improvements in AQLQ(S) score (mean 0.73), morning and evening PEF (mean 42.5 and 24.8?L/min, respectively), and symptom-severity score (mean 0.36) were achieved during run-in. The improvements were maintained in both groups although, overall, adjustable-dosing patients took fewer daily inhalations of budesonide/formoterol than fixed-dosing patients (mean 2.63 versus 3.82, p < 0.001).

Conclusion: Adjustable maintenance dosing with budesonide/formoterol maintains HRQL and asthma control as effectively as fixed dosing and is associated with a reduced drug load overall.     

Systematic review and meta-analysis of budesonide/formoterol in a single inhaler

ABSTRACT

Objective: To compare the effectiveness of budesonide/formoterol using fixed dosing (BUD/FORM) with inhaled corticosteroid (ICS) alone or alternative ICS and long-acting β₂-agonist (LABA) regimens for adults with moderate/severe asthma.

Methods: BIOSIS, CENTRAL, EMBASE and MEDLINE were searched for abstracts and papers. All searching was completed in July 2006. No restriction was placed on language. Meta-analysis of randomised controlled trials (RCTs) using a fixed effects model. RCTs were included if the comparator with BUD/FORM had an equivalent daily dose of ICS at the start of the trial. The primary outcome measure was, ‘treatment failure’, defined as: asthma-related serious adverse event, oral glucocorticosteroid treatment, A&E visit and/or admission to hospital, withdrawal due to a need for additional asthma therapy.

Results: Of the 330 papers identified in the literature search, 15 met the inclusion criteria. The following alternative treatments were found: ICS alone (BUD), BUD/FORM adjustable maintenance dose (BUD/FORM-AMD), and salmeterol/fluticasone in a single inhaler (SALM/FP). Meta-analysis of treatment failure demonstrated a 50% increase with BUD versus BUD/FORM (Relative Risk [RR] 1.50, 95% confidence interval [95% CI]: 1.12–2.02, p = 0.007; 2 RCTs); a trend in favour of a reduction with BUD/FORM-AMD versus BUD/FORM (RR 0.88, 95% CI: 0.77–1.02, p = 0.09; 11 RCTs); and no evidence of a difference with SALM/FP versus BUD/FORM (RR 0.99, 95% CI: 0.83–1.16, p = 0.86; 3 RCTs). Significant heterogeneity was not detected in the primary analyses. Secondary analyses demonstrated the following significant differences: hospitalisations/A&E visits (49% increased risk with SALM/FP vs. BUD/FORM, RR 1.49, 95% CI: 1.07–2.08, p = 0.02, and 28% reduced risk with BUD/FORM-AMD vs. BUD/FORM, RR 0.72, 95% CI: 0.52–0.99, p = 0.04); and use of oral steroids (51% increase in risk with BUD vs. BUD/FORM, RR 1.51, 95% CI: 1.10–2.09, p = 0.01, and 19% reduced risk with BUD/FORM-AMD vs. BUD/FORM, RR 0.81, 95% CI: 0.70–0.95, p = 0.01).

Conclusions: Fixed-dose BUD/FORM is an effective treatment option for adult patients with moderate/severe asthma when compared to BUD and SALM/FP, with adjustable maintenance dosing demonstrating important advantages over fixed dosing in relation to exacerbation prevention and reduced treatment load.     

吸入布地奈德／福莫特罗和布地奈德／沙丁胺醇对哮喘急性发作儿童支气管扩张的效果探讨

目的比较吸入布地奈德（100μg）／福莫特罗（6μg）、布地奈德（100μg）／沙丁胺醇（100μg）组合在5—15岁儿童哮喘发作期对支气管扩张的效果。方法采用双盲随机对照试验,研究组给予使用布地奈德100μg＋福莫特罗6μg组合压力式定量气雾装置吸入（MDI）,对照组给予布地奈德100μg＋沙丁胺醇100μg组合MDI。所有的儿童接受三次剂量的药物,给药间隔时间在20分钟以内。分析比较FEV1（％预计值）以及修正的肺指标值（MPIS）,研究两组在1、5、15、30、60分钟后的药效。结果干预后两组之间1、5、15、30、60分钟FEV1（％预计值）的比较差异无统计学意义（P〉0．05）。而对照组、研究组自身的（FEV1％预计值）绝对变化值,从基线到60分钟的差值为（12．2±2．5）以及（9．4±2．0）,两组比较差异有统计学意义（t=3．50,P〈0．05）。在两组基线相比,1、5、15、30、50分钟,从基线FEV1百分比变化也相似。呼气峰流速（PEFR）,百分比预测PEFR,用力呼气流速50（FEF50）和百分比预测FEF50,在两组相似研究过程中不同时间点也相似。其他肺功能参数两组之间比较差异无统计学意义。结论沙丁胺醇或福莫特罗,在二定吸入剂量的作用下,对轻度哮喘急性发作期5～15岁之间的儿童,有类似的支气管扩张作用。     

Efficacy and safety profile of fluticasone/formoterol combination therapy compared to its individual components administered concurrently in asthma: a randomised controlled trial

Abstract

Background:

The potent inhaled corticosteroid, fluticasone propionate (fluticasone), and the long-acting β₂-agonist with a rapid onset of action, formoterol fumarate (formoterol), have now been combined in a single aerosol inhaler, fluticasone/formoterol (flutiform). This study investigated the efficacy and safety of fluticasone/formoterol combination therapy compared with its individual components administered concurrently via two separate inhalers.     

Validation of a RP-HPLC method for the assay of formoterol and its related substances in formoterol fumarate dihydrate drug substance

A stability-indicating reversed-phase high performance liquid chromatographic (HPLC) method has been developed and validated for the assay of formoterol fumarate and the related substances, namely, formoterol fumarate desformyl and formoterol fumarate acetamide analogs, in the active pharmaceutical ingredient. The separation was achieved by isocratic elution using an Alltech Alltima C₁₈ (150×4.6 mm) column, a mobile phase consisting of ammonium acetate (50 mM; pH 5.0)–ethanol (65:35, v/v), a flow rate of 1.0 ml/min and UV detection at 242 nm. The detection and quantitation limits were 0.03 and 08 μg/ml, respectively, while the linear range of detection was between 0.03 and 255 μg/ml. Comparative determinations of formoterol fumarate in three lots of bulk drugs using the proposed HPLC method and the standard potentiometric titration method of pharmacopoeia show that both methods are equivalent for pure drug substance assay. However, the HPLC method allowed the separation and quantitation of the impurities not achievable with the official methods in the bulk drugs. This study shows that the proposed method is accurate, linear, and sensitive as stability indicating assay method for formoterol fumarate in the bulk drug.     

福莫特罗治疗哮喘急性发作临床分析

目的 了解富马酸福莫特罗在儿童中、重度哮喘息性发作中的作用。方法 以盐酸丙卡特罗为对照，观察5～10岁哮喘患儿服药起效时间、持续时间、有效性和安全性。结果 57例中、重度哮喘息性发作儿童口服富马酸福莫特罗后2h症状体征的改善情况、呼吸峰流速值改善情况、1周后夜间睡眠改善情况优于对照组，两组差异有意义，12h症状体征的改善、呼吸峰流速值改善情况、总体疗效与对照组之间无显著差异．未发现明显不良反应。结论 富马酸福莫特罗和盐酸丙卡特罗在疗效及副作用方面一致，其起效时间明显快于盐酸丙卡特罗．对夜间睡眠改善情况明显优于盐酸丙卡特罗，对儿童中重度哮喘急性发作具有较好的疗效。     

阿奇霉素联合布地奈德福莫特罗在支气管哮喘治疗中的作用

目的 观察阿奇霉素与布地奈德福莫特罗联合治疗支气管哮喘的疗效与安全性.方法 将50例中重度支气管哮喘患者完全随机分为单药组和联合组,每组25例.单药组以布地奈德福莫特罗治疗,联合组以阿奇霉素联合布地奈德福莫特罗治疗.观察2组治疗后症状改善情况和肺功能变化及不良反应.结果 单药组和联合组治疗1周及3个月后,哮喘症状评分均明显低于治疗前[单药组日间症状:(0.96±0.78)、(0.50±0.40)分比(3.76±1.16)分;单药组夜间症状:(0.76±0.38)、(0.22±0.02)分比(3.32±0.18)分;联合组日间症状:(0.56±0.51)、(0.28 ±0.08)分比(4.04±0.84)分;联合组夜间症状:(0.52±0.25)、(0.04 ±0.03)分比(3.44±0.20)分],1 s用力呼气容积/用力肺活量(FEV1/FVC)均明显高于治疗前[单药组:(65.5±2.0)％、(73.8±1.4)％比(58.5±1.8)％;联合组:(68.7±1.3)％、(82.1±0.8)％比(58.2±1.8)％],差异均有统计学意义(均P ＜0.05).治疗1周及3个月后,联合组哮喘症状评分明显低于单药组,FEV1/FVC明显高于单药组,差异均有统计学意义(均P＜0.05).2组在治疗期间未发生严重不良反应.结论 阿奇霉素联合布地奈德福莫特罗治疗支气管哮喘疗效确切,不良反应少.     

咳喘舒片联合布地奈德福莫特罗治疗支气管哮喘的临床研究

目的 探讨咳喘舒片联合布地奈德福莫特罗吸入粉雾剂治疗支气管哮喘的临床疗效.方法 选择2020年2月—2021年2月在天津宁河区医院治疗的102例支气管哮喘患者为研究对象,采用双色球法分为对照组和治疗组,每组各51例.对照组吸入布地奈德福莫特罗吸入粉雾剂(Ⅱ),2吸/次,必要时增至4吸,2次/d;治疗组在对照组的基础上口...     

布地奈德/福莫特罗在改善急性发作期哮喘患儿肺功能和临床症状中的应用

目的观察布地奈德/福莫特罗(信必可都宝)改善急性发作期哮喘患儿的肺功能以及症状中的疗效。方法选择年龄大于6岁、符合哮喘急性发作期患儿40例,吸入布地奈德/福莫特罗2吸后分别于5、20、35 min作基础肺功能检查,观察肺部听诊哮鸣音改善效果。结果所有患儿在吸入布地奈德/福莫特罗后35 min内肺功能得到明显好转,支气管舒张试验呈阳性,肺部哮鸣音减少,其中28例患儿在吸入布地奈德/福莫特罗后5 min内起效,另12例患儿在吸入后20 min内起效,其肺功能均得到改善,支气管舒张试验呈阳性。结论布地奈德/福莫特罗能快速缓解急性发作期哮喘患儿肺功能和临床症状,与病情轻重、吸入有效剂量有关。     

Concomitant occasional use of salbutamol influences bronchoprotective responsiveness afforded by formoterol in patients with the glycine-16 genotype

Background Predisposition to subsensitivity with long-acting ₂-agonists (LABA) or regular short-acting ₂-agonists (SABA) is related to polymorphisms at codon 16 of the ₂-adrenoceptor.Objective To determine whether the use of occasional SABA induces further baseline downregulation of the ₂-adrenoceptor to that of endogenous catecholamines alone, in Gly-16 patients.Methods A post-hoc analysis of two studies was performed. Twenty-three homozygous Gly-16 asthmatic patients received 12 g inhaled formoterol either o.d. or b.i.d. for 2 weeks. Patients had been supplied with ipratropium bromide (IB) to use as reliever therapy preferentially over salbutamol. Spirometry and adenosine monophosphate (AMP) bronchial challenge was performed after 7–14 days of placebo and after active treatment.Results A review of domiciliary diary card data indicated 13 patients (mean FEV₁: 76.8% pred., AMP PC₂₀: 23.4 mg/ml) did not require salbutamol, and 10 patients (mean FEV₁: 77.9% pred., AMP PC₂₀: 27.9 mg/ml) required occasional salbutamol (1.67 puffs/day) during run-in and/or formoterol periods. No significant difference in spirometry or AMP PC₂₀ were found between the populations after placebo. After formoterol, compared with placebo, patients requiring occasional salbutamol had no improvement in AMP PC₂₀ [geometric mean PC₂₀ (and 95% CI): 28.0 mg/ml (20.5–38.4) versus 34.46 mg/ml (25.1–47.3)], while those patients not requiring salbutamol had a significant (p<0.05) improvement in AMP PC₂₀ with formoterol compared with placebo [89.9 mg/ml (52.4–154.3) versus 30.6 mg/ml (17.8–52.5)]. This amounted to a 3.12-fold (95% CI: 0.16–6.07) geometric mean fold difference between groups.Conclusions Our results indicate that homozygous Gly-16 patients using occasional salbutamol have reduced responsiveness to formoterol in terms of bronchoprotection to AMP than patients not using salbutamol. Patients expressing the homozygous gly-16 genotype of the ₂-adrenoceptor genotype receiving a LABA may benefit from the substitution of their usual SABA for an alternative reliever.     

十味龙胆花颗粒联合布地奈德福莫特罗粉治疗支气管哮喘的临床研究

目的探讨十味龙胆花颗粒联合布地奈德福莫特罗粉治疗支气管哮喘的临床疗效。方法选择2018年1月—2019年1月在北京怀柔医院治疗的支气管哮喘患者82例,根据用药的差别分为对照组(41例)和治疗组(41例)。对照组给予布地奈德福莫特罗粉吸入剂,2吸/次,2次/d;治疗组在对照组的基础上口服十味龙胆花颗粒,3 g/次,3次/d。两组患者均治疗2周。观察两组患者临床疗效,同时比较治疗前后两组患者WHOQOL-BREF、LCQ、MARS-A和C-ACT评分,血清基质金属蛋白酶组织抑制剂-1(TIMP-1)、半胱氨酰白三烯(Cys LTs)、降钙素原(PCT)、白细胞介素-4(IL-4)和白细胞介素-6(IL-6)水平,以及一秒用力呼气容积(FEV1)、用力肺活量(FVC)和最大呼气流量(PEF)水平。结果治疗后,对照组临床有效率为80.49%,显著低于治疗组的97.56%,两组比较差异有统计学意义(P0.05)。经治疗,两组患者LCQ、MARS-A、C-ACT和WHOQOL-BREF评分均明显升高(P0.05),且治疗组患者这些评分明显高于对照组(P0.05)。经治疗,两组患者血清TIMP-1、Cys LTs、PCT、IL-4、IL-6水平均明显降低(P0.05),且治疗组患者这些血清学指标水平明显低于对照组(P0.05)。经治疗,两组患者FEV1、FVC、PEF水平均明显升高(P0.05),且治疗组患者这些肺功能指标明显好于对照组(P0.05)。结论十味龙胆花颗粒联合布地奈德福莫特罗粉吸入剂治疗支气管哮喘可有效改善患者临床症状,促进肺功能改善,促进患者生活质量提高,具有一定的临床推广应用价值。     

24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol

ABSTRACT

Objective: To assess the bronchodilator efficacy, safety and tolerability of indacaterol, a novel, once-daily inhaled β₂-agonist bronchodilator, in patients with chronic obstructive pulmonary disease (COPD).

Methods: This crossover, double-blind, double-dummy study was conducted to evaluate the 24-h bronchodilator effect of a range of single doses of indacaterol (150?µg, 300?µg and 600?µg), given in the morning via single-dose dry powder inhaler (SDDPI) in subjects with COPD, compared with placebo and with the daily therapeutic dose of formoterol (two 12?µg doses 12?h apart, via an SDDPI). Tolerability and safety were also assessed.

Results: Fifty-one subjects with moderate-to-severe COPD received each of the five treatments on separate study days in randomised sequence. The 24-h trough FEV₁ (primary endpoint; mean [95%?CI]) was 1.46 (1.43, 1.49)?L with indacaterol 600?µg (p?<?0.001 vs. placebo, p?<?0.01 vs. formoterol, p?<?0.05 vs. indacaterol 150?µg), 1.45 (1.42, 1.48)?L with indacaterol 300?µg (p?<?0.001 vs. placebo, p?<?0.05 vs. formoterol), 1.42 (1.39, 1.45)?L with indacaterol 150?µg (p?<?0.001 vs. placebo), 1.41 (1.38, 1.43)?L with formoterol (p?<?0.001 vs. placebo) and 1.28 (1.25, 1.31)?L with placebo. All treatments were well tolerated and there was little effect on serum potassium, blood glucose or QTc interval.

Conclusion: All doses of indacaterol were effective in providing 24-h bronchodilation and were well-tolerated in subjects with COPD. The bronchodilator efficacy of indacaterol (150, 300 and 600?μg) at 24?h post-dose was at least as efficacious as formoterol 12?µg twice daily.     

Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV1 reversibility

SUMMARY

Background: Recent studies suggest that inspiratory capacity (IC) measured at rest can be used to predict improvements in dyspnea and exercise tolerance in chronic obstructive pulmonary disease (COPD) patients. In this study we compared the effect of formoterol (Foradil* Aerolizer*) and salmeterol (Sereventt Diskust) in terms of IC in patients with COPD.

Methods: This was a multicentre, randomized, placebo-controlled, single-dose, double-dummy, crossover study conducted in five secondary care centres in four European countries. A total of 47 patients with Stage II and III COPD, as defined by ATS criteria, with an increase in forced expiratory volume in 1?s (FEV1) of <12% from the patient's predicted normal value after salbutamol inhalation were included. Patients inhaled single doses of formoterol (12 and 24?ng), salmeterol (50 and 100 jug) or matching placebo. IC was recorded before dosing and at 5,10,15 and 30min and 1, 2, 3 and 4?h post-dose.

Results: Formoterol was significantly superior to salmeterol during the first hour post-dose as indicated by notable differences at all times during the first hour post-dose and by the ANCOVA analysis of the Area Under the IC Curve (AUCMh).

Conclusions: Both formoterol and salmeterol increase IC in patients with COPD, with formoterol 12|ig showing a significantly greater increase in IC over the first hour post-dose than salmeterol 50|ig, consistent with a more rapid onset of action.     

不同规格布地奈德/福莫特罗吸入剂治疗哮喘的经济学与装置依从性评价

目的：对不同规格布地奈德/福莫特罗吸入剂治疗哮喘患者进行疗效与经济学评价,评估药师在提高吸入装置依从性中的作用。方法：将52例中重度哮喘患者随机分成A、B 2组,分别吸入布地奈德/福莫特罗（160/4.5 μg）每次2吸,bid,及布地奈德/福莫特罗（320/9 μg）每次1吸,bid,治疗时间为12周。分别于第0周、4周和12周,观察哮喘控制测试问卷（asthma control test,ACT）评分和不良反应发生情况,以评价2组的疗效和安全性;统计治疗期间产生的医疗费用做成本分析;对患者吸入装置操作步骤进行干预,并采用问卷形式进行吸入装置依从性评价。结果：治疗前后相比,2组患者ACT评分获得了显著改善;A组和B组的不良反应发生率分别为26.92%和23.08%;而B 组12周人均每日治疗费用更低;经过药师的干预后,2组患者装置依从性显著提高。结论：布地奈德/福莫特罗（320/9 μg）成本-效果比最低,是治疗中重度哮喘的最佳选择。药师在提高哮喘患者吸入装置依从性过程中发挥重要作用。     

哮喘儿童血清特异性IgE检测结果分析

目的 了解本地区哮喘儿童的过敏原，为预防和治疗儿童哮喘提供依据。方法对我院儿科哮喘门诊89例哮喘患儿按年龄分为儿童组和幼儿组，进行了吸入性、食物性过敏原体外血清特异性IgE抗体检测。结果吸入性过敏原以尘螨的所占比例较高，为35．96％，其次是蟑螂、飞蛾、蜜蜂，所占比例为19．11％；食物性过敏原以草菇、冬菇、金针菇和牛奶所占比例较高（17．65％、15．69％），且尘螨所占比例在儿童组最高，为40．54％；牛奶、羊奶所占比例在婴幼儿组最高，为33．34％，两组相比较差异有统计学意义（P〈0．05）。结论尘螨是本地区引起儿童哮喘的主要过敏原，在儿童哮喘组蟑螂、飞蛾、蜜蜂也是主要的过敏原；牛奶、羊奶、草菇、冬菇是婴幼儿哮喘发作不能忽略的重要因素。     

寒喘祖帕颗粒联合布地奈德福莫特罗治疗支气管哮喘的临床研究

目的探讨寒喘祖帕颗粒联合布地奈德福莫特罗粉吸入剂治疗支气管哮喘的临床疗效。方法选取2016年2月—2017年2月在玉田县医院进行治疗的哮喘患者113例为研究对象,所有患者根据用药的差别分为对照组(56例)和治疗组(57例)。对照组吸入布地奈德福莫特罗粉吸入剂,初始2吸/次,症状控制后调整为1吸/次,2次/d。治疗组在对照组基础上口服寒喘祖帕颗粒,1袋/次,2次/d。两组患者均治疗1个月。观察两组的临床疗效,比较两组的临床症状消失时间、C反应蛋白(CRP)、炎性因子和肺功能。结果治疗后,对照组和治疗组的总有效率分别为82.14%、96.49%,两组比较差异具有统计学意义(P0.05)。治疗后,治疗组咳嗽消失时间、哮鸣音消失时间、呼吸困难缓解时间均显著短于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组血清CRP、白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)水平均显著降低,同组治疗前后比较差异具有统计学意义(P0.05);且治疗组这些观察指标明显低于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组用力呼气量占用力肺活量比值(FEV1/FVC)、最大呼气流速(PEF)和用力肺活量(FVC)均显著升高,同组治疗前后比较差异有统计学意义(P0.05);且治疗组这些观察指标明显高于对照组,两组比较差异具有统计学意义(P0.05)。结论寒喘祖帕颗粒联合布地奈德福莫特罗粉吸入剂治疗支气管哮喘具有较好的临床疗效,能改善肺功能,缩短临床症状消失时间,调节炎性因子水平,具有一定的临床推广应用价值。